Levi Downs, MD
Gynecologic Oncology · St Louis Park, MNNPI 1700816311
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,050 of the $107,705 with a category attached, or 91.0%. AstraZeneca accounts for 99.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $78,888 and has fallen 99.7% since, to $208 in 2025. Among gynecologic oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $1682.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$107K
- Coopersurgical, Inc.$120
- Intuitive Surgical$89
- Tesaro, Inc.$47
- Merck$18
What the payments were for
- Consulting fees$2,3982%
- Speaking & faculty fees$98,05091%
- Travel & lodging$5,3385%
- Food & beverage$1,8822%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $107,432 |
| Coopersurgical, Inc. | 1 | $120 |
| Intuitive Surgical | 1 | $89 |
| Tesaro, Inc. | 1 | $47 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$106,551
- ALLY II UPS$120
How this compares
$107,705 in reported general payments places this provider in the 95th percentile of 39 gynecologic oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 44 | $892 |
| Megestrol Acetate | 14 | $589 |
| Dexamethasone | 87 | $396 |
| Ondansetron Hcl | 42 | $221 |
| Olanzapine | 81 | $158 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in St Louis Park
- Nabila RasoolSt Louis Park$287
- Jamie Bakkum-GamezRochester$51K
- Lori WeinbergCoon Rapids$47K
- Ebrahim VersiEden Prairie$32K
- Britt EricksonMinneapolis$28K
- William ClibyRochester$15K
- Melissa GellerMinneapolis$14K
- Emily PrendergastMinneapolis$10K
- Carrie LangstraatRochester$6K
- Colleen Rivard HuntMinneapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.